ArticleInternational journal of surgery (London, England)2026
Deciphering CD4+ Naive T cell-mediated divergent pathogenic links between type 2 diabetes and pathologic scarring via an integrated multi-omics approach.
Article in International journal of surgery (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Nucleotide Metabolism in Health and Disease.MedComm · 2026Review
- The immunometabolic tipping point: forecasting the systemic shift from psoriasis to psoriatic arthritis.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to investigate the causal relationship between diabetes mellitus and pathological scarring, including hypertrophic scars (HS) and keloids, and to elucidate the underlying immune cellular mechanisms and key molecular regulators.
methodsWe employed a phenome-wide Mendelian randomization approach (MR-PheWAS) to identify potential causal links between diabetes and pathological scars. Separate Mendelian randomization meta-analyses (MR-Meta) were performed for type 1 diabetes (T1D) and type 2 diabetes (T2D). Integrative analyses incorporating single-cell RNA sequencing (scRNA-seq), cell-cell communication inference, metabolic pathway profiling, and transcriptomic differential expression and enrichment analyses were conducted to delineate scar heterogeneity mediated by diabetes-related cellular subpopulations and molecular drivers.
resultsMR-PheWAS revealed significant causal associations between HS and multiple diseases. T2D exhibited a positive causal association with HS (OR: 1.13, 95% CI: 1.09-1.17, P < 0.0001), and a negative association with keloids (OR: 0.95, 95% CI: 0.92-0.99, P = 0.016). T1D showed no significant causal relationship with either scar type. Single-cell analysis identified an upregulation of CD4+ Naive T cells (CD4+ NT) in HS and a downregulation in keloids. This subset exhibited strong interactions with endothelial cells in both scar types, primarily enriched in the insulin signaling pathway (INS-INSR) signaling axis. Three pivotal genes (GPR35, TMEM91, and ZBTB32) were identified as overlapping molecular links between T2D and pathological scars, all expressed in CD4+ NT and showing inverse expression trends across HS and keloids. Pseudotime trajectory analysis further revealed divergent expression kinetics of these genes, characterized by early loss and late-phase upregulation. Metabolic pathway analysis implicated these genes in modulating metabolic reprogramming of the CD4+ NT population, thereby influencing scar differentiation.
conclusionConvergent multi-omics evidence supports the hypothesis that T2D exerts opposing causal effects on different forms of pathological scarring, potentially mediated through CD4+ NT. The transcriptomic features, intercellular communication profiles, key gene signatures, and metabolic landscape of this subset collectively suggest that T2D may contribute to divergent fibrotic pathways in HS and keloids via immune microenvironmental modulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.